News

2019.01.14

Chairman Fei-Kai Syu awarded “China Outstanding Innovative Entrepreneur 2018” in Beijing China.

Chairman Fei-Kai Syu awarded “China Outstanding Innovative Entrepreneur 2018” during China New Economic Brands Summit held in Beijing China.
0001
0001
20190114003_改革創新示範單位2

20190114002_優秀企業家2

2019.01.12

FKS Life and Health Medical Care is now part of the honored group of companies, on MedTech Outlook: Medical Imaging 2018. 

Please visit the link below:

MedTech Outlook: Medical Imaging 2018

0001

2019.01.03

Chairman Syu interviewed by MED TECH.

20180103_FKS-Life and Health Medical Care (H)20190103_fks life and health medical care

2018.10.1

Taiwan Society of Anesthesiologists Annual meeting

9/29~9/30  TSA successfully held
FKS successfully exhibited FKScope and invited many doctors to visit the products on site.

S__20471819

S__20471820

S__20471825

S__20471826

S__20471821

S__20471822

S__20471823

S__20471824

2018.09.26

LKL collaborates with FKS Medical Care to market medical device

TheEdgeWed, Sep 26, 2018 – 4 days ago

KUALA LUMPUR (Sept 26): LKL International Bhd, through its subsidiary LKL Advance Metaltech Sdn Bhd, has inked a collaborative memorandum of understanding (MoU) with FKS Medical Care Sdn Bhd to cooperate in the market development of Sanuwave Health Inc’s dermaPACE, an advanced medical device used to treat acute and chronic wounds.

In a filing with Bursa Malaysia today, LKL said under the two-year MoU, FKS will be responsible for introducing dermaPACE into Malaysia, and both FKS and LKL Advance Metaltech will cooperate together to promote and market the device in the country.

FKS Medical Care is a subsidiary of FKS-Life & Health Medical Care Inc, a medical appliance and device manufacturer and distributor based in California, the US.

LKL said dermaPACE is a shock wave technology using a patented system of non-invasive, high energy, acoustic shock waves for regenerative medicine and other applications.

The dermaPACE system is cleared by the US Food and Drug Administration for marketing in the US for the treatment of diabetic foot ulcers. The system is CE Marked for the European Union, and licensed in Canada, Australia, New Zealand and South Korea for acute and chronic conditions of the skin and subcutaneous soft tissue indications.

LKL managing director Lim Kon Lian said he is optimistic the device will be well received in Malaysia, and provide more advanced wound care treatment for conditions such as post traumatic wounds, burns and diabetic ulcers, bringing better healthcare and greater quality of life to patients.

“Additionally, the inclusion of dermaPACE to our medical devices portfolio is in line with our strategy to provide comprehensive solutions to our customers in the healthcare sector.

“We would also continue to identify opportunities to introduce more high-value medical products to the Malaysia market,” he said.

LKL shares closed up one sen or 7.4% to 14.5 sen today, for a market capitalisation of RM62 millions.

http://www.klsescreener.com/v2/news/view/435532


4/19

Our company’s latest artificial intelligence technology for anesthesia endotracheal intubation will be exhibited on 4/19 at New York NY ASRA

Our Boston Office

In response to the company’s rapid growth and business needs.
We have a new office in Boston.

One International Place
Suite 1400,
Boston, MA 02110

One International place

%d bloggers like this: